I’m interested to see efficacy results that start this quarter on the sublingual tablet against chronic pain syndrome. Also, I am excited how it will compare with GWPH ‘s drug if their amendment is granted. Zevi is also pushing MM along. So many reasons to keep a core amount of shares. I will say I’m not enthused about efficacy on the cream starting in Q3.

I’m hopeful since the tablet is 100 percent OWCP and managements that it’s studies move along at a much more rapid pace unlike the cream that is partially owned by Sheba. Let’s see if the tablet safety study timeline follows Closer to their predictions.